The MM-II trial was carried out in partnership with Israel-based Moebius Medical and included 397 patients in the US, Europe, ...

Revenue from operations increased 10% YoY on the back of strong deal wins and strong growth in key geographies and verticals ...

The company’s net non-performing assets (NPAs) stood at 1.46% as of March 2025, up from 0.99% in the same quarter last year ...

Revenue in the quarter was at ₹15,213 crore, recording a 2.4% year-on-year growth over the same quarter a year ago ...